

# Special Issue

## Advances in Cardiac Remodeling

### Message from the Guest Editors

Cardiac remodeling involves an adaptive heart process to maintain myocardial performance in response to different stimuli, not only clinical circumstances but also environmental, dietary, and effort demands. In this context, remodeling is characterized by time-dependent evolution and consists of several adaptive changes, clinically represented by modifications of cardiac form, size, and performance.

In this context, the current Special Issue intends to publish articles reporting on recent advances in cardiac remodeling as a process secondary to nutritional and/or metabolic conditions such as dietary interventions, obesity, and diabetes. From this perspective, papers based on experimental models, clinical trials, or applied studies focused on the assessment and prevention of and interventions for different conditions are very welcome to be submitted to this Special Issue. Likewise, original research papers, reviews focused on phenotypical adaptive alterations, and innovations in terms of molecular mechanisms and clinical relevance configuring potential issues are also welcome to be submitted.

---

### Guest Editors

Dr. Silvio Assis de Oliveira-Junior

School of Physical Therapy, Federal University of Mato Grosso do Sul—UFMS, Campo Grande 79070-900, MS, Brazil

Dr. André Soares Leopoldo

Postgraduate Program in Nutrition and Health and Physiological Science, Health Sciences Center, Federal University of Espírito Santo, Vitória 29075-910, ES, Brazil

---

### Deadline for manuscript submissions

31 March 2026



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/253171](https://mdpi.com/si/253171)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).